Trial record 1 of 72 for:    Open Studies | "Bacteremia"
Previous Study | Return to List | Next Study

Virulence Determinants in S Aureus Bacteremia

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Duke University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00319826
First received: April 27, 2006
Last updated: January 14, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to investigate why some people develop life-threatening infections caused by the bacteria Staphylococcus aureus, while other people do not. It is possible that the infectious ability of the bacteria can determine whether an infection develops and its severity. The investigators will look at old blood and nasal specimens collected from 1000 adults who had S. aureus infections and who were hospitalized at Duke University Medical Center. Previously collected health information regarding these patients and the specific bacterial traits in the samples will be studied. Eventually this information may be used to help treat and prevent S. aureus infection.


Condition Intervention
Bacteremia
Other: No intervention

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Virulence Determinants in Staphylococcus Aureus Bacteremia

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • Cure vs. recurrence of Staph infection vs. death [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood samples


Estimated Enrollment: 10000
Study Start Date: March 2004
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Subjects with Staphylococcus Bacteremia
2
Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
Other: No intervention
This is an observational study with no intervention
Other Name: Observational Study

Detailed Description:

The purpose of this study is to more thoroughly investigate the impact of bacterial genetic characteristics on the outcome of patients with S. aureus bacteremia (SAB). The investigators will address salient aspects of bacterial virulence using strong collaborative relationships with authorities in bacterial genetics and genomics. The overall hypothesis of this investigation is that distinct bacterial virulence determinants influence the severity of S. aureus infection. The specific hypothesis is that virulence determinants associated with clinical outcome of S. aureus infection segregate into clonal groups, identified by Multilocus Sequence Typing (MLST), and can be localized in the genome by comparative genetic hybridization (CGH). The investigators have established the following aims to pursue this hypothesis. Specific Aim 1: Define the allelic diversity of S. aureus bloodstream isolates using MSLT. Allelic profiles among the 1000 isolates will be compared using the program BURST (Based Upon Related Sequence Type), and relatedness of lineages in the overall collection will be defined. Specific Aim 2: Define the genomic diversity of S. aureus bloodstream isolates using CGH. Using MLST results, a subset of 200 isolates will be selected to undergo further study. These ~200 isolates will form a unique collection hereafter referred to as the SAGA (S. aureus genomic analysis) collection. The genomic diversity of the SAGA subset will be defined using CGH. Specific Aim 3: Correlate MLST and CGH results, MLST and clinical outcome, and CGH, and clinical outcome, and make SAGA isolates available to the scientific community. In this Specific Aim, the discriminate ability of MLST and CGH will be compared among the SAGA subset isolates undergoing both assays. The association between bacterial clonality and clinical outcome will be considered among 1000 S. aureus isolates collected from adults at Duke University Medical Center who had S. aureus infections undergoing MLST. The association between clinical outcome and the presence or absence of virulence factors and pathogenicity islands in the S. aureus genome will also be considered among the 200 SAGA subset isolates undergoing CGH. The products of this study will include an increased understanding of genetic diversity in S. aureus and the role of this genetic diversity on determining the severity of infections caused by S. aureus. The full value of the current proposal also includes the potential future benefit to the research community as a whole if associations between pathogen genotype and clinical outcome, only possible to identify using such a large and clinically well-characterized collection of isolates, can be defined. To amplify these potential downstream dividends, the final goal of Specific Aim 3 will be to make SAGA subset isolates, corresponding MLST types, and CGH profiles available to the scientific community through the repository maintained by the Network for Antimicrobial Resistance in S. aureus (NARSA). The long-term objectives of this project are to: (1) identify bacterial genes contributing to the severity of infection in isolates from a large cohort of patients with SAB; and (2) ultimately use these genes to identify novel interventions for the control of S. aureus pathogenesis by investigating genes that govern the virulence of this emerging pathogen. Culture-confirmed SAB nasal carriage isolates and/or bloodstream bacterial isolates previously collected from 1000 inpatient adults at Duke University Medical Center will be used in this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Bacterial strains are used from patients with particular syndromes (e.g. nasal carraige, endocarditis, osteomylitis) that were be identified using the Bloodstream Infections Registry. No new subjects was or will be enrolled within the current investigation.

Criteria

Inclusion Criteria:

  1. Adults (>= 18 years) with culture-confirmed Staphylococcus aureus bacteremia (SAB). Patients with SAB transferred to Duke University Medical Center are eligible if speculation and antibiotic susceptibilities are confirmed by the Duke Clinical Microbiology Laboratory.
  2. Absolute neutrophil count of > 1000 cells/cubic millimeter at the time that the initial positive blood culture is obtained.
  3. Patient or patient's representative provides signed informed consent allowing study participation.

Exclusion Criteria:

  1. Prior enrollment of patient in this investigation (to ensure statistical independence of observations).
  2. Staphylococcus aureus bacteremia (SAB) that is not confirmed by culture and speciation at the Duke Clinical Microbiology Laboratory.
  3. Outpatient status.
  4. Isolation of any pathogen other than S. aureus from bloodstream.
  5. Inability of patient or patient's representative to provide written informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00319826

Contacts
Contact: Vance Fowler (919) 684-2549
Contact: Felicia Ruffin, MSN 919-684-4487 ruffi006@mc.duke.edu

Locations
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Investigators
Principal Investigator: Vance G. Fowler, MD Duke UMC
  More Information

No publications provided

Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT00319826     History of Changes
Other Study ID Numbers: Pro00014073 (04-087)
Study First Received: April 27, 2006
Last Updated: January 14, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Duke University:
Staphylococcus aureus, S. aureus, bacteremia, sepsis

Additional relevant MeSH terms:
Bacteremia
Bacterial Infections
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on August 19, 2014